Maxim Group Reiterats Bullish Stance on Galmed (GLMD) Following FDA Fast-Track Status; Funded Through Proof-of-Concept Studies in NASH
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $24 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
